Actavis, Inc. to Host Second Quarter 2013 Earnings Conference Call and Webcast
PARSIPPANY, N.J., June 28, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), announced today that it intends to release second quarter 2013 financial results on Thursday, July 25, 2013, prior to the open of the U.S. financial markets. The Company will host a conference call and webcast at 8:30 a.m. Eastern Time on Thursday, July 25, 2013 to discuss its financial results. The dial-in number to access the call is US/Canada (877) 251-7980, International (706) 643-1573, and the Conference ID is 12382077.
A taped replay of the conference call will also be available beginning approximately two hours after the call's conclusion and will remain available through 12:00 midnight Eastern Time on August 8, 2013. The replay may be accessed by dialing (855) 859-2056 and entering pass code 12382077. From international locations, the replay may be accessed by dialing (404) 537-3406 and entering the same pass code. To access the webcast, go to Actavis' Investor Relations Web site at http://ir.actavis.com. A replay of the webcast will also be available.
About Actavis, Inc.
Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. Actavis has global headquarters in Parsippany, New Jersey, USA.
Operating as Actavis Pharma, Actavis develops, manufactures and markets generic, branded generic, legacy brands and Over-the-Counter (OTC) products in more than 60 countries. Actavis Specialty Brands is Actavis' global branded specialty pharmaceutical business focused in the Urology and Women's Health therapeutic categories. Actavis Specialty Brands also has a portfolio of five biosimilar products in development in Women's Health and Oncology. Actavis Global Operations has more than 30 manufacturing and distribution facilities around the world, and includes Anda, Inc., a U.S. pharmaceutical product distributor.
For press release and other company information, visit Actavis' Web site at http://www.actavis.com.
SOURCE Actavis, Inc.